We can learn a number of things from the update in Life Science Leader Magazine;
* Centyrex has gone from strength to strength. Apart from the say-so within the article, we can see that from their increased profile at conferences.
* The key therapeutic targets are in oncology. Using the address to be given by Robert Hayes at the Proteins & Antibodies Conference as a guide, it is highly probable that Centyrex is targeting intracellular proteins e.g. intracellular kinases and IAPs (refer 5 June 2013 presentation).
janssen presentation on centyrins, page-26
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $839.8M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.5¢ | 17.5¢ | $681.3K | 3.798M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 332130 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 469568 | 4 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PYC (ASX) Chart |